These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34498246)

  • 41. [Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?].
    Coriat R; Chaussade S
    Therapie; 2007; 62(2):105-9. PubMed ID: 17582310
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase.
    Shrestha S; Zhang C; Jerde CR; Nie Q; Li H; Offer SM; Diasio RB
    Clin Pharmacol Ther; 2018 Oct; 104(4):709-718. PubMed ID: 29327356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population.
    Elraiyah T; Jerde CR; Shrestha S; Wu R; Nie Q; Giama NH; Sarangi V; Roberts LR; Offer SM; Diasio RB
    Clin Pharmacol Ther; 2017 Mar; 101(3):382-390. PubMed ID: 27727460
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
    Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
    J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction.
    Gentile G; Botticelli A; Lionetto L; Mazzuca F; Simmaco M; Marchetti P; Borro M
    Pharmacogenomics J; 2016 Aug; 16(4):320-5. PubMed ID: 26216193
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.
    Lunenburg CA; van Staveren MC; Gelderblom H; Guchelaar HJ; Swen JJ
    Pharmacogenomics; 2016 May; 17(7):721-9. PubMed ID: 27181275
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
    Boisdron-Celle M; Capitain O; Faroux R; Borg C; Metges JP; Galais MP; Kaassis M; Bennouna J; Bouhier-Leporrier K; Francois E; Baumgaertner I; Guerin-Meyer V; Cojocarasu O; Roemer-Becuwe C; Stampfli C; Rosenfeld L; Lecompte T; Berger V; Morel A; Gamelin E
    Semin Oncol; 2017 Feb; 44(1):13-23. PubMed ID: 28395758
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Dihydropirymidine dehydrogenase (DPD)--a toxicity marker for 5-fluorouracil?].
    Jedrzychowska A; Dołegowska B
    Ann Acad Med Stetin; 2013; 59(2):48-53. PubMed ID: 25026750
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine].
    Boisdron-Celle M; Morel A; Gamelin E
    Ann Biol Clin (Paris); 2010; 68(1):27-32. PubMed ID: 20146975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dihydropyrimidine dehydrogenase 85T>C mutation is associated with ocular toxicity of 5-fluorouracil: a case report.
    Baskin Y; Amirfallah A; Unal OU; Calibasi G; Oztop I
    Am J Ther; 2015; 22(2):e36-9. PubMed ID: 24434920
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
    Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
    Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.
    Zhang H; Li YM; Zhang H; Jin X
    Med Oncol; 2007; 24(2):251-8. PubMed ID: 17848752
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.
    Ezzeldin H; Johnson MR; Okamoto Y; Diasio R
    Clin Cancer Res; 2003 Aug; 9(8):3021-8. PubMed ID: 12912951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients.
    Katona C; Kralovánszky J; Rosta A; Pandi E; Fónyad G; Tóth K; Jeney A
    Oncology; 1998; 55(5):468-74. PubMed ID: 9732227
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
    Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
    Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
    Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; van Werkhoven E; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
    Eur J Cancer; 2019 Jan; 107():60-67. PubMed ID: 30544060
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase.
    Del Re M; Restante G; Di Paolo A; Crucitta S; Rofi E; Danesi R
    Curr Pharm Des; 2017; 23(14):2028-2034. PubMed ID: 28128059
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
    Henricks LM; van Merendonk LN; Meulendijks D; Deenen MJ; Beijnen JH; de Boer A; Cats A; Schellens JHM
    Int J Cancer; 2019 May; 144(9):2347-2354. PubMed ID: 30485432
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.
    Saif MW; Diasio RB
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):151-6. PubMed ID: 27278667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.